Fall term update 2016
Thanks to the successful financing round of CHF 3.3 million in May 2016, the InnoMedica team was able to further advance the Talidox project in the last few months and to gain fundamental progress in the fields of preclinical, clinical development and analytics. Particularly pleasing are the results of the animal model studies, which show a high effect of liposomal targeting and suggest new possibilities of application in the clinic.
- Stable production confirmed by consistent results in several preclinical studies: InnoMedica’s Talidox achieves a constantly better effect than today’s treatment standards. Measurements in a fast-growing, metastasizing tumor model also yielded promising results: Treatment with Talidox showed only half as many metastases compared to a treatment with Caelyx.
- Results of in vitro studies with new 3D models could explain the expected better side-effects profile as well as better biodistribution of Talidox compared to Caelyx.
- A research collaboration with an American university was initiated. First data show that InnoMedica’s liposomal targeting technology allows the blood-brain barrier to be overcome, thus opening up applications for neurodegenerative diseases such as Parkinson’s or Alzheimer’s disease.
- InnoMedica’s first liposomal formulation of the active agent Doxorubicin, calledTalidox, is being prepared for clinical application in collaboration with Swiss Oncologists of the SAKK. The toxicology study is already well advanced in planning.
- To strengthen the scientific team, InnoMedica recruited two chemists in the third quarter of 2016: Andreas König and Dr. Florian Weiss.
- In InnoMedica’s production facility at the Marly Innovation Center, the department of analytics was supplemented with new devices and methods. In addition, a chemical synthesis laboratory with a focus on glycan technology will be set up.
- InnoMedica plans to carry out a further capital increase of CHF 7.7 million in spring 2017 to generate capital for the clinical trials.
Read more about this in our newsletter.
We have come closer to our goal of making this promising technology usable for patients – with a first product in the field of oncology (on its way into the clinics) and a second in the field of neurodegenerative diseases (in cooperation with an American university).
Follow our progress and receive all news by email – sign up now